Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentations April 19, 2026 08:00 ET | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta, April 19, 2026 (GLOBE NEWSWIRE) Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the Euro

April 09, 2026 08:30 ET | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta , April 09, 2026 (GLOBENEWSWIRE) Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, intends to present a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the upcoming European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) congress in Munich, Germany. “The preclinical results we

By Gina Shaw Original Source: FPI-2119 investigational antibiotic A novel antibiotic that targets penicillin-binding proteins (PBPs) without relying on a beta-lactam scaffold demonstrated broad in-vitro activity, bactericidal effects, low resistance selection, and encouraging in-vivo efficacy across a series of preclinical studies presented at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation, in Las Vegas, on Jan. 29, 2026. Across four relat

FPI-2119 offers potential solution to multi-drug-resistant Gram-negative infections Original source: https://www.globenewswire.com/news-release/2026/01/29/3228557/0/en/Fedora-Pharmaceuticals-Highlights-Efficacy-of-Novel-Antibiotic-FPI-2119-against-Antimicrobial-resistant-Gram-negative-Bacteria-at-the-2026-IMARI-Conference.html January 29, 2026 08:12 ET | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a

January 13, 2026 08:00 ET | Source: Fedora Pharmaceuticals, Inc. Original Source: https://www.globenewswire.com/news-release/2026/01/13/3217762/0/en/Fedora-Pharmaceuticals-has-Re-emerged-to-Unveil-Novel-Class-of-Antibiotics-at-2026-Interdisciplinary-Meeting-on-Antimicrobial-Resistance-and-Innovation-IMARI.html Edmonton, Alberta, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, annou

Originally published on the Canadian Antimicrobial Innovation Coalition (CAIC) website. To mark World Antimicrobial Awareness Week,...

Public awareness is growing in Canada and around the world about the urgent need for concerted global action to counter the serious...

EDMONTON, Alberta – Fedora Pharmaceuticals, Inc. announced they have received nonrefundable financial contribution from the National...

Originally published on the National Research Council of Canada. EDMONTON, Alberta - Doctors around the world are starting to speak with...

Originally published on the Review on Antimicrobial Resistance. Antimicrobials, and specifically antibiotics, play a crucial role in...

EDMONTON, Alberta - Fedora Pharmaceuticals Receives Alberta Life Sciences "Company of the Year" Award EDMONTON, Alberta – November 30,...

EDMONTON, Alberta – November 9, 2015 – Fedora Pharmaceuticals Inc., a biotechnology company headquartered in Edmonton, Alberta, Canada,...

Originally published on Roche.com BASEL, Switzerland - Roche (SIX: RO, ROG; OTCQX: RHHBY), Meiji Seika Pharma (Meiji) and Fedora...

Findings Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) EDMONTON, Alberta – September 12, 2013 –...

EDMONTON, Alberta – October 31, 2012 – Fedora Pharmaceuticals, Inc. today announced the creation of a Board of Directors and appointment...

EDMONTON, Alberta – September 5, 2012 – Fedora Pharmaceuticals, Inc. today announced the appointment of Thomas Parr, Ph.D. to the newly...